News

May 2017 Newsletter

I am personally committed to making the IASLC as effective as possible at accomplishing its mission of reducing the impact of thoracic cancers worldwide.

Robert L. Comis, MD, passed away suddenly in his home on May 10, 2017. He was 71.

Geneva, Switzerland, 05 May 2017 – White blood cell counts can predict whether or not lung cancer patients will benefit from immunotherapy, according to research presented at the European Lung Cancer Conference (ELCC).

Geneva, Switzerland, 05 May 2017 – Osimertinib improves cancer-related symptoms in patients with advanced lung cancer, according to an analysis of patient-reported outcomes from the AURA3 phase III clinical trial presented today at the European Lung Cancer Conference.

Geneva, Switzerland, 05 May 2017 – Some advanced lung cancer patients benefit from immunotherapy even after the disease has progressed as evaluated by standard criteria, according to research presented at the European Lung Cancer Conference (ELCC).1 The findings pave the way for certain patients to continue treatment if the disease is not progressing according to new, more specific, criteria.

Geneva, Switzerland, 04 May 2017 - Patients with advanced non-small-cell lung cancer (NSCLC) who require salvage chemotherapy are 30% more likely to achieve a partial response if they have been pre-treated with a PD-1/PD-L1 checkpoint inhibitor compared to those who have not, according to a study presented today at the European Lung Cancer Conference (ELCC) 2017 in Geneva, Switzerland

Pages